P1/2, N=315, Not yet recruiting, Shanghai Zhongshan Hospital

P1/2, N=30, Completed, Eli Lilly and Company | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Jan 2026

Although the primary endpoint was not met, the combination provided durable control of MPE and was well tolerated, suggesting potential value in symptom-focused management of this high-risk subgroup.

We describe a 75-year-old man with advanced lung adenocarcinoma who developed multiple bleeding pyogenic granulomas during docetaxel plus ramucirumab therapy. This intra-patient contrast suggests that VEGFR-2 blockade and VEGF ligand inhibition may have different effects on paradoxical vascular proliferative lesions. Clinicians should recognize this rare toxicity and consider switching anti-angiogenic strategy in selected cases.

However, the sample size is relatively small and needs to be increased for further research. https://clinicaltrials.gov/study/NCT03986515, identifier NCT03986515.

P2, N=124, Recruiting, Air Force Military Medical University, China

In summary, the combination of Apa and Ade represented a promising innovative therapeutic strategy for SCLC.

Ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor-2 (VEGFR-2), has shown a survival benefit when combined with docetaxel in patients with previously treated advanced NSCLC. Collectively, these agents highlight the expanding role of antibody-based therapies in NSCLC and underscore the importance of biomarker-driven patient selection and treatment personalization. Ongoing research into resistance mechanisms, predictive biomarkers, and combination approaches is expected to further refine the integration of antibody-based strategies in precision oncology for NSCLC.

P1/2, N=43, Completed, Washington University School of Medicine | Active, not recruiting --> Completed

P1/2, N=170, Recruiting, Ottimo Pharma Limited | N=41 --> 170

Herein, a dual-targeting ultrasonic nanoconverter (OPD@PSF) is elaborately engineered through in situ polymerization to co-deliver a sonosensitizer protoporphyrin IX (PpIX) and a stimulator of interferon genes (STING) agonist Vadimezan (DMXAA) to achieve dual-zone programmed sono-STING immunotherapy (DPSSI) in tumors and tdLNs...Additionally, DMXAA-mediated STING activation stimulates antigen-presenting cells, acting synergistically with ROS-driven SDT to eradicate primary tumors and suppress metastatic dissemination. By optimizing the US parameters, the rationally designed OPD@PSF exemplifies a new nanotechnological strategy for synergistic breast cancer therapy and metastasis suppression via tumor/tdLN dual-targeted delivery and systemic immune orchestration, holding great promise for clinical translation.

Combining a GPR34 antagonist with chemotherapy and surufatinib significantly enhanced anti-tumor responses in preclinical models. These findings identify GPR34 as a promising immune therapeutic target.